BioPortBioPort
  • Schedule
  • Sponsors
  • No menu assigned!

IMV Inc.

  • 0 Shares Share
    0
  • 0

IMV Inc. (formerly known as Immunovaccine Inc.) develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform. DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the capability for single-dose effectiveness. The DepoVax platform possesses impressive flexibility, allowing it to work with a broad range of target antigens in various therapeutic applications. The technology is also commercially scalable, with potential for years of stability and ease of use in the clinic.

  • Previous Project
  • Next Project

© 2023 BioNova | Contact

  • Schedule
  • Sponsors